Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,651-1,700 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_C3,5 | Lung | Primary cancer | 279 | Stromal | 80.3% | 0.83 | 0.39 |
| NSCLC_38242124__IMC__87_C3,6 | Lung | Primary cancer | 2,612 | Tumor/Malignant | 52.2% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_C3,7 | Lung | Primary cancer | 3,981 | Stromal | 27.6% | 0.47 | 0.94 |
| NSCLC_38242124__IMC__87_C3,8 | Lung | Primary cancer | 2,734 | Immune | 29.6% | 0.40 | 0.91 |
| NSCLC_38242124__IMC__87_C3,9 | Lung | Primary cancer | 4,620 | Tumor/Malignant | 73.7% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_C4,1 | Lung | Primary cancer | 2,293 | Tumor/Malignant | 56.3% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_C4,10 | Lung | Primary cancer | 2,721 | Tumor/Malignant | 62.0% | 0.97 | 0.16 |
| NSCLC_38242124__IMC__87_C4,11 | Lung | Primary cancer | 2,834 | Tumor/Malignant | 45.3% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__87_C4,12 | Lung | Primary cancer | 2,917 | Tumor/Malignant | 64.7% | 0.91 | 0.25 |
| NSCLC_38242124__IMC__87_C4,13 | Lung | Primary cancer | 3,295 | Tumor/Malignant | 45.0% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__87_C4,14 | Lung | Primary cancer | 750 | Other | 35.6% | 0.87 | 0.33 |
| NSCLC_38242124__IMC__87_C4,16 | Lung | Primary cancer | 6,103 | Immune | 91.9% | 1.00 | 0.01 |
| NSCLC_38242124__IMC__87_C4,17 | Lung | Primary cancer | 385 | Other | 45.7% | 0.82 | 0.40 |
| NSCLC_38242124__IMC__87_C4,2 | Lung | Primary cancer | 551 | Tumor/Malignant | 46.3% | 0.90 | 0.28 |
| NSCLC_38242124__IMC__87_C4,3 | Lung | Primary cancer | 3,857 | Tumor/Malignant | 50.1% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__87_C4,4 | Lung | Primary cancer | 3,605 | Tumor/Malignant | 45.4% | 0.92 | 0.28 |
| NSCLC_38242124__IMC__87_C4,5 | Lung | Primary cancer | 3,092 | Tumor/Malignant | 75.8% | 0.95 | 0.15 |
| NSCLC_38242124__IMC__87_C4,6 | Lung | Primary cancer | 127 | Stromal | 55.1% | 0.43 | 0.66 |
| NSCLC_38242124__IMC__87_C4,9 | Lung | Primary cancer | 3,113 | Tumor/Malignant | 65.0% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__87_C5,1 | Lung | Primary cancer | 3,641 | Immune | 27.1% | 0.86 | 0.34 |
| NSCLC_38242124__IMC__87_C5,10 | Lung | Primary cancer | 3,696 | Tumor/Malignant | 70.7% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__87_C5,11 | Lung | Primary cancer | 3,291 | Tumor/Malignant | 45.6% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__87_C5,13 | Lung | Primary cancer | 2,805 | Stromal | 33.5% | 0.74 | 0.62 |
| NSCLC_38242124__IMC__87_C5,14 | Lung | Primary cancer | 3,037 | Tumor/Malignant | 41.6% | 0.86 | 0.40 |
| NSCLC_38242124__IMC__87_C5,15 | Lung | Primary cancer | 4,236 | Stromal | 26.2% | 0.33 | 1.01 |
| NSCLC_38242124__IMC__87_C5,16 | Lung | Primary cancer | 1,093 | Stromal | 61.1% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__87_C5,17 | Lung | Primary cancer | 598 | Other | 48.2% | 0.90 | 0.33 |
| NSCLC_38242124__IMC__87_C5,2 | Lung | Primary cancer | 3,450 | Tumor/Malignant | 37.8% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_C5,3 | Lung | Primary cancer | 3,023 | Stromal | 36.0% | 0.91 | 0.27 |
| NSCLC_38242124__IMC__87_C5,4 | Lung | Primary cancer | 1,785 | Tumor/Malignant | 61.7% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__87_C5,5 | Lung | Primary cancer | 3,452 | Tumor/Malignant | 45.4% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__87_C5,6 | Lung | Primary cancer | 3,550 | Tumor/Malignant | 33.8% | 0.75 | 0.58 |
| NSCLC_38242124__IMC__87_C5,7 | Lung | Primary cancer | 2,241 | Tumor/Malignant | 57.0% | 0.94 | 0.24 |
| NSCLC_38242124__IMC__87_C5,8 | Lung | Primary cancer | 3,137 | Immune | 30.7% | 0.46 | 0.71 |
| NSCLC_38242124__IMC__87_C6,1 | Lung | Primary cancer | 3,792 | Immune | 40.6% | 0.89 | 0.31 |
| NSCLC_38242124__IMC__87_C6,10 | Lung | Primary cancer | 3,131 | Tumor/Malignant | 58.8% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__87_C6,12 | Lung | Primary cancer | 2,686 | Stromal | 28.3% | 0.73 | 0.62 |
| NSCLC_38242124__IMC__87_C6,14 | Lung | Primary cancer | 3,652 | Tumor/Malignant | 60.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__87_C6,15 | Lung | Primary cancer | 4,008 | Immune | 25.0% | 0.43 | 0.88 |
| NSCLC_38242124__IMC__87_C6,16 | Lung | Primary cancer | 452 | Stromal | 40.5% | 0.47 | 0.84 |
| NSCLC_38242124__IMC__87_C6,2 | Lung | Primary cancer | 3,274 | Tumor/Malignant | 94.5% | 0.99 | 0.02 |
| NSCLC_38242124__IMC__87_C6,3 | Lung | Primary cancer | 2,696 | Immune | 29.8% | 0.49 | 0.85 |
| NSCLC_38242124__IMC__87_C6,4 | Lung | Primary cancer | 3,429 | Stromal | 48.6% | 0.99 | 0.08 |
| NSCLC_38242124__IMC__87_C6,5 | Lung | Primary cancer | 2,711 | Immune | 25.3% | 0.52 | 0.82 |
| NSCLC_38242124__IMC__87_C6,6 | Lung | Primary cancer | 3,726 | Tumor/Malignant | 51.2% | 0.91 | 0.27 |
| NSCLC_38242124__IMC__87_C6,7 | Lung | Primary cancer | 4,231 | Tumor/Malignant | 39.6% | 0.83 | 0.36 |
| NSCLC_38242124__IMC__87_C6,8 | Lung | Primary cancer | 3,103 | Tumor/Malignant | 47.8% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__87_C6,9 | Lung | Primary cancer | 2,531 | Tumor/Malignant | 39.7% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__87_C613 | Lung | Primary cancer | 1,117 | Tumor/Malignant | 41.7% | 0.61 | 0.71 |
| NSCLC_38242124__IMC__87_C7,1 | Lung | Primary cancer | 4,244 | Tumor/Malignant | 52.2% | 0.96 | 0.15 |